Adsorption on apatitic calcium phosphates for drug delivery: interaction with bisphosphonate molecules.
Bisphosphonates (BPs) are well established as an important class of drugs for the treatment and prevention of several bone disorders including osteoporosis. This work investigated the interaction of two bisphosphonates, risedronate and tiludronate, with several apatitic supports, a well-crystallised hydroxyapatite (HA) and nanocrystalline apatites with varying maturation times, chemical composition and surface characteristics. The purpose was to fully understand the adsorption mechanism and desorption process, by the evaluation of the effect of several physicochemical parameters (temperature, pH and concentration of calcium and phosphate ions). Whatever the nature of the BP and the structure and composition of the apatite, the adsorption of such anti-resorptive agents can be well described as an ion exchange-reaction between phosphates species on the apatitic surface and BP molecules in solution. However, the parameters of adsorption can vary depending on the physicochemical conditions of the adsorption reaction. In addition, the structure and composition of the apatitic surface also influence the adsorption properties. Finally, BPs molecules are slowly released from apatitic supports, because most of the adsorbed molecules are irreversibly bound and not spontaneously released by dilution or simple washing. Moreover, similar to their adsorption, the release of bisphosphonates is strongly affected not only by the chemical properties of the molecule, but also by the chemical and structural characteristics of the apatitic substrates. The understanding of the adsorption and release processes provides fundamental tools for the development of drug delivery systems using apatite materials.
CIRIMAT INPT-CNRS-UPS, Université de Toulouse, Université Paul Sabatier, 31062, Toulouse, France.
P
P
Pascaud
F
F
Errassifi
F
F
Brouillet
S
S
Sarda
A
A
Barroug
A
A
Legrouri
C
C
Rey
D000327:Adsorption; D001031:Apatites / Q000737:chemistry*; D002130:Calcium Phosphates / Q000737:chemistry*; D003692:Delayed-Action Preparations; D004164:Diphosphonates / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics*; D016503:Drug Delivery Systems; D004347:Drug Interactions; D012968:Etidronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000737:chemistry / Q000493:pharmacokinetics; D000068296:Risedronic Acid; D013997:Time Factors
D001031:Apatites; D002130:Calcium Phosphates; D003692:Delayed-Action Preparations; D004164:Diphosphonates; C058651:tiludronic acid; D000068296:Risedronic Acid; D012968:Etidronic Acid